The global pulmonary drug delivery systems market size is expected to reach USD 72.33 billion by 2030, registering a CAGR of 4.6% from 2024 to 2030. Increasing prevalence of chronic respiratory diseases is expected to boost the adoption of Pulmonary Drug Delivery Systems (PDDS). As per WHO, 235 million people suffer from asthma globally. Majority of the asthma-related deaths occur in middle- to low-income countries due to a lack of treatment options. This shows the potential demand for pulmonary drug delivery systems in the coming years.
Technological advancements in the field of drug delivery are expected to positively impact the pulmonary drug delivery devices market. These advancements include the incorporation of agglomerated vesicle technology, MDI electronic dose counter, particle engineering, and supercritical fluid technology. Rising demand for new products, changing lifestyle, ease of use, and better facilities are factors expected to provide lucrative opportunities.
Furthermore, a rise in the number of public and private organizations is another major factor propelling the growth of the pulmonary drug delivery devices market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology. Such initiatives are in turn expected to increase the market demand for respiratory drug delivery devices in developing regions, thereby boosting the overall market growth.
This product will be delivered within 1-3 business days.
Technological advancements in the field of drug delivery are expected to positively impact the pulmonary drug delivery devices market. These advancements include the incorporation of agglomerated vesicle technology, MDI electronic dose counter, particle engineering, and supercritical fluid technology. Rising demand for new products, changing lifestyle, ease of use, and better facilities are factors expected to provide lucrative opportunities.
Furthermore, a rise in the number of public and private organizations is another major factor propelling the growth of the pulmonary drug delivery devices market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology. Such initiatives are in turn expected to increase the market demand for respiratory drug delivery devices in developing regions, thereby boosting the overall market growth.
Pulmonary Drug Delivery Systems Market Report Highlights
- The inhalers segment accounted for the largest market share of 62.8% in 2023. Unlike injections which circulate in the bloodstream, inhalers administer medicine straight to the lungs.
- The nebulizers segment is expected to register the fastest CAGR of 5.4% during the forecast period.
- The Chronic Obstructive Pulmonary Disease (COPD) segment accounted for the largest market share in 2023. COPD is a chronic disease that requires continuous treatment and care.
- The asthma segment is projected to grow at the fastest CAGR over the forecast period. Asthma patients look for treatment options that are easy to carry and use, in their everyday routines.
- The hospitals & clinics segment dominated the market in 2023. The treatment offered by doctors in hospitals and clinics helps in speedy recovery of patients.
- North America pulmonary drug delivery systems market dominated the market with the largest revenue share of 32.0% in 2023. The increasing cases of chronic diseases such as asthma and CODP is attributing to the market growth in the region.
- Asia Pacific pulmonary drug delivery systems market anticipated to witness significant growth. The continuous increase in the number of asthmatic and allergic rhinitis patients are factors expected to propel the market growth.
The leading players in the Pulmonary Drug Delivery Systems market include:
- 3M
- AstraZeneca
- GSK plc.
- Novartis AG
- Koninklijke Philips N.V.
- Boehringer Ingelheim International GmbH.
- Teva Pharmaceutical Industries Ltd.
- OMRON Healthcare, Inc.
- PARI GmbH
- Cipla
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Pulmonary Drug Delivery Systems Market Variables, Trends, & Scope
Chapter 4. Pulmonary Drug Delivery Systems Market: Product Estimates & Trend Analysis
Chapter 5. Pulmonary Drug Delivery Systems Market: Application Estimates & Trend Analysis
Chapter 6. Pulmonary Drug Delivery Systems Market: End Use Estimates & Trend Analysis
Chapter 7. Pulmonary Drug Delivery Systems Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
The leading players in the Pulmonary Drug Delivery Systems market include:- 3M
- AstraZeneca
- GSK plc.
- Novartis AG
- Koninklijke Philips N.V.
- Boehringer Ingelheim International GmbH.
- Teva Pharmaceutical Industries Ltd.
- OMRON Healthcare, Inc.
- PARI GmbH
- Cipla
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 53.24 Billion |
| Forecasted Market Value ( USD | $ 72.33 Billion |
| Compound Annual Growth Rate | 4.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
